获得性突变驱动系统性自身炎症性疾病:重新定义疾病图谱
本研究对2017至2025年间转诊至国家级自身炎症性疾病参考中心的5530例患者进行深度二代测序自身炎症基因panel检测以发现低水平嵌合。5530例中403例(7.3%,95%CI 6.6%-8.0%)确诊SAID,其中83例(20.6%,95%CI 16.9%-24.8%)检出嵌合变异,包括VEXAS综合征(69%)、CAPS(24%)、TRAPS(5%)、Blau综合征(1%)和NLRC4炎症小体病(1%)。结论认为体细胞嵌合是迟发型SAID的常见机制,常诊断延迟且AA淀粉样变风险高。
要点
- SAID患者中嵌合变异检出率达20.6%,以VEXAS综合征和CAPS为主。
- 迟发型嵌合CAPS患者中20%并发AA淀粉样变,提示需警惕。
- 发现首例由性腺嵌合导致的TRAPS垂直传播病例。
核心结论
- 体细胞嵌合是迟发型系统性自身炎症性疾病的常见机制,此类疾病常诊断延迟且AA淀粉样变风险高。
研究设计与样本
- 2017至2025年间转诊至国家级SAID参考中心的5530例患者接受深度二代测序自身炎症基因panel检测以发现低水平嵌合,结果经多学科复核并与电子病历临床数据关联。
主要发现
- 5530例中403例(7.3%,95%CI 6.6%-8.0%)确诊SAID,其中83例(20.6%,95%CI 16.9%-24.8%)检出嵌合变异。
- 嵌合变异见于VEXAS综合征(69%)、CAPS(24%)、TRAPS(5%)、Blau综合征(1%)和NLRC4炎症小体病(1%)。
- 报告首例由性腺嵌合导致的TRAPS垂直传播病例。
- 迟发型嵌合CAPS患者中20%病程并发AA淀粉样变。
关键数值与推荐
- SAID诊断率7.3%(95%CI 6.6%-8.0%),嵌合变异在SAID患者中检出率20.6%(95%CI 16.9%-24.8%)。
- 嵌合变异在VEXAS综合征中占69%、CAPS中占24%、TRAPS中占5%、Blau综合征中占1%、NLRC4炎症小体病中占1%。
- 迟发型嵌合CAPS患者AA淀粉样变发生率为20%。
临床怎么用
- 对迟发型SAID患者应进行深度测序检测低水平嵌合变异。
- 嵌合CAPS患者需监测AA淀粉样变并发症。
- 识别性腺嵌合对TRAPS的家系遗传咨询具有重要意义。
局限性
- 本研究为单中心遗传异质性队列,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Mosaicism is a recognized cause of systemic autoinflammatory diseases (SAIDs). Initially described in cryopyrin-associated periodic syndromes (CAPS), it has since been reported in several dominantly inherited SAIDs, including Blau syndrome, tumor necrosis factor receptor-associated periodic syndrome (TRAPS), stimulator of interferon genes-associated vasculopathy with onset in infancy, NLRC4 inflammasomopathies, and familial Mediterranean fever. Recently, somatic variants underlying vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) have extended this to late-onset disease. This study aimed to characterize the prevalence, spectrum, and clinical significance of acquired variants in SAIDs. METHODS: A total of 5,530 patients referred to a national SAIDs reference center between 2017 and 2025 underwent deep next-generation sequencing autoinflammatory gene panel testing to detect low-level mosaicism. Results underwent multidisciplinary review and correlation with clinical data from electronic medical records. RESULTS: SAID diagnoses were made in 403 of 5,530 patients (7.3%, 95% confidence interval [CI] 6.6%-8.0%). Among these, mosaic variants were identified in 83 patients (20.6%, 95% CI 16.9%-24.8%), including patients with VEXAS syndrome (69%), CAPS (24%), TRAPS (5%), Blau syndrome (1%), and NLRC4 inflammasomopathies (1%). Twenty-three distinct mosaic variants were identified across different SAIDs genes; in eight, the minor allele frequency was ≤5%. We report the first case of vertical transmission of TRAPS due to gonosomal mosaicism. AA amyloidosis complicated the disease course in 20% of patients diagnosed with late-onset mosaic CAPS. CONCLUSION: Somatic mosaicism is a frequent mechanism underlying late-onset SAIDs, which are often diagnosed late and carry a high risk of AA amyloidosis. To our knowledge, this represents the largest genetically heterogeneous single-center cohort of individuals with mosaic SAIDs reported to date.
引用
- Rowczenio D, Omoyinmi E, Brown J, et al. Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases. Arthritis Rheumatol. 2026. PMID: 42529936. doi:10.1002/art.70282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。